Biotech - Oncology
•324 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (324)
%
| Company | Market Cap | Price |
|---|---|---|
|
Biotech - Oncology: Corvus's pipeline includes ITK-targeted cancer therapies (PTCL), indicating oncology focus.
|
$569.88M |
$7.39
+11.30%
|
|
Arvinas' lead programs target cancer (ER degrader vepdegestrant, BCL6 degrader ARV-393, KRAS G12D degrader ARV-806) using PROTACs; core oncology product line.
|
$548.90M |
$7.52
-2.59%
|
|
Direct oncology-focused biotech product line via MNPR-101 platform and cancer-targeted radiopharmaceuticals.
|
$537.04M |
$87.82
-14.34%
|
|
Company focuses on oncology therapeutics leveraging protein engineering platforms.
|
$516.07M |
$35.38
-0.76%
|
|
Rigel's portfolio centers on oncology/hematology therapies (e.g., GAVRETO, REZLIDHIA) and includes pipeline assets in cancer, placing it squarely in Biotech - Oncology.
|
$503.65M |
$28.18
-0.77%
|
|
Verastem focuses on oncology therapeutics, with AVMAPKI FAKZYNJA CO-PACK as its lead product in cancer.
|
$470.91M |
$8.57
-7.45%
|
|
ABS-501 (anti-HER2) and other oncology-focused assets place Absci in Biotech - Oncology.
|
$469.42M |
$3.68
-8.46%
|
|
LY T-200 is a first-in-class monoclonal antibody for oncology, a core PureTech asset (Gallop Oncology) in the pipeline.
|
$464.27M |
$18.00
|
|
Tivumecirnon's oncology program places RAPT in the Biotech - Oncology category.
|
$443.00M |
$26.79
-10.52%
|
|
Lead product approved for relapsed/refractory B-ALL places the company firmly in oncology.
|
$441.79M |
$1.66
-6.21%
|
|
Cullinan Therapeutics is a clinical-stage biotech focused on oncology, with assets including bispecific T-cell engagers and a targeted EGFR inhibitor, directly aligning with Biotech - Oncology.
|
$436.71M |
$7.40
+4.23%
|
|
Company’s focus on oncology (NMIBC) places it in Biotech - Oncology as a cancer therapy developer.
|
$428.77M |
$8.39
-5.20%
|
|
ADCT operates in oncology/biotech focusing on cancer therapies (e.g., DLBCL, indolent lymphomas).
|
$404.65M |
$4.36
+6.86%
|
|
Core oncology-focused therapeutics with DANYELZA (anti-GD2).
|
$389.89M |
$8.61
|
|
Company focused on oncology therapeutics (immuno-oncology agents).
|
$388.95M |
$4.77
-1.65%
|
|
iTeos Therapeutics is an oncology-focused biotech developing cancer immunotherapies, including anti-TIGIT antibodies and other immuno-oncology assets.
|
$388.48M |
$10.15
|
|
Company operates in oncology-focused interventional therapy space (liver-dominant cancers, mUM, mCRC, mBC).
|
$374.21M |
$10.74
-0.78%
|
|
Biotech - Oncology: company-focused on oncology radiopharmaceuticals and cancer therapies.
|
$360.75M |
$4.86
+15.71%
|
|
The company targets cancer immunotherapy for GBM and other solid tumors, i.e., oncology-focused biotech.
|
$358.65M |
$0.25
+2.66%
|
|
Replimune is a cancer-focused biotechnology company developing oncolytic immunotherapies, aligning with Biotech - Oncology.
|
$352.29M |
$4.67
+2.30%
|
|
TOI's core business is oncology care and cancer therapies, aligning with the Biotech - Oncology investable theme.
|
$338.20M |
$3.79
-4.05%
|
|
Portfolio includes partnered oncology candidates (etigilimab, navicixizumab), aligning with Biotech - Oncology.
|
$311.64M |
$1.96
-6.67%
|
|
Candel Therapeutics focuses on oncology using viral immunotherapies (CAN-2409, CAN-3110).
|
$310.14M |
$6.19
-6.07%
|
|
Lead programs target oncology indications (cancer) via galectin-3 inhibition; core business focus.
|
$298.74M |
$4.72
-1.05%
|
|
Aura's lead program bel-sar is a cancer therapy targeting solid tumors, representing its core oncology business.
|
$297.59M |
$5.92
-2.95%
|
|
Immutep develops oncology immunotherapies (eftilagimod alfa) for cancer, aligning with Biotech - Oncology.
|
$292.57M |
$2.01
-2.90%
|
|
Company's oncology-focused CAR-T programs targeting B-cell malignancies (ALL and NHL).
|
$291.26M |
$4.04
-3.81%
|
|
Lead oncology candidate MIE-101 immunotherapy platform directly positions the company in Biotech - Oncology.
|
$280.13M |
$0.70
|
|
PEDMARK is an FDA-approved oncology therapy addressing cisplatin-induced ototoxicity in pediatric patients, making Biotech - Oncology the core product offering.
|
$272.87M |
$9.82
-0.56%
|
|
Pipeline focused on oncology indications (LBCL, RCC) using CAR T cell therapies.
|
$269.04M |
$1.23
-14.58%
|
|
Company is positioned in Oncology biotech with a focus on innovative cancer therapies.
|
$266.05M |
$3.30
+1.23%
|
|
The company operates in oncology-focused biotech with LBCL programs, aligning with Biotech - Oncology.
|
$262.11M |
$17.75
+11.99%
|
|
Puma Biotechnology directly develops oncology therapies and commercializes NERLYNX, a cancer drug, aligning with Biotech - Oncology.
|
$254.15M |
$5.12
-2.29%
|
|
Sagimet Biosciences designs and develops FASN inhibitors (denifanstat, TVB-3567) for metabolic diseases and oncology, aligning with Biotech - Oncology.
|
$247.10M |
$7.67
-10.96%
|
|
OncotoX platform indicates an oncology-focused pipeline and preclinical oncology programs.
|
$245.50M |
$4.19
-8.71%
|
|
Vor Biopharma's core focus is oncology therapies developed via engineered cell/gene therapies for blood cancers.
|
$234.05M |
$37.46
+1.57%
|
|
Company is a clinical-stage oncology biotech developing MasterKey targeted cancer therapies (BDTX-1535, BDTX-4933).
|
$232.57M |
$4.09
-6.41%
|
|
Company is a clinical-stage biotechnology firm focused on oncology therapies (MICVO ADC).
|
$229.21M |
$3.70
-3.39%
|
|
Foghorn Therapeutics is a clinical-stage biotech focused on oncology therapies targeting the chromatin regulatory (epigenetic) system, aligning with Biotech - Oncology.
|
$226.31M |
$4.06
-8.76%
|
|
Company focus on oncology with a Deep Cyclic Inhibition approach targeting the MAPK pathway.
|
$220.59M |
$6.13
-2.23%
|
|
Directly develops oncology-focused biotech therapies (NEO100, NEO212) and a BBB-penetrating platform for brain cancers.
|
$219.38M |
$11.53
-1.11%
|
|
Directly developing oncology therapies via gene-edited cell therapies (CAR-T), i.e., Biotech - Oncology.
|
$213.91M |
$2.30
+5.50%
|
|
The company's therapeutic focus is oncology, aligning with Biotech - Oncology as a primary disease area for its cancer therapies.
|
$206.13M |
$4.47
|
|
TARA-2.00 is an immunopotentiating cell therapy platform for cancer (NMIBC), representing a direct product in oncology.
|
$201.40M |
$5.22
-8.42%
|
|
Heron Therapeutics' main products are oncology supportive-care drugs (CINVANTI, SUSTOL) and NK1 receptor antagonist APONVIE for post-operative nausea/vomiting, aligning with Biotech - Oncology.
|
$195.28M |
$1.28
-2.29%
|
|
Company is positioned as an oncology-focused biotech with innovative immuno-oncology assets.
|
$193.61M |
$1.67
-9.73%
|
|
Genelux develops oncolytic viral immunotherapies for cancer, anchored by Olvi-Vec, fitting Biotech - Oncology.
|
$191.32M |
$5.07
-7.82%
|
|
GPS and SLS009 are oncology-focused therapeutics developed by SELLAS Life Sciences.
|
$190.58M |
$1.91
-1.04%
|
|
CRBP's core strategy focuses on oncology therapies, including targeted antibody–drug conjugates and immunotherapy approaches.
|
$190.16M |
$15.54
-2.08%
|
|
Fate Therapeutics develops oncology-focused cellular therapies (CAR-T) using an iPSC-derived, off-the-shelf platform.
|
$187.42M |
$1.64
+0.31%
|
|
Company focuses on oncology therapeutics using targeted protein degradation, placing it in Biotech - Oncology.
|
$171.84M |
$2.42
-6.20%
|
|
Company is a biotech focused on oncology immunotherapies leveraging a platform (AMP) for cancer treatment.
|
$169.25M |
$10.58
-5.11%
|
|
CGEN's core business is immuno-oncology, developing antibody-based therapies (e.g., COM701) and advancing IO assets.
|
$165.64M |
$1.85
-5.13%
|
|
Innate Pharma's core pipeline is oncology-focused, including monoclonal antibodies and antibody-based immunotherapies (lacutamab and monalizumab).
|
$164.36M |
$2.03
+2.53%
|
|
Company focuses on oncology delivery technologies (PEDD) and has an investigational immunotherapy asset (nelitolimod), placing it in Oncology/Biotech domains.
|
$163.46M |
$4.32
-2.26%
|
|
CytoDyn's leronlimab is a CCR5-targeting biologic being developed for oncology, fitting Biotech - Oncology.
|
$163.45M |
$0.27
+2.97%
|
|
Company's SORT1+ oncology platform with TH1902 (sudocetaxel zendusortide) positions Theratechnologies in oncology drug development.
|
$155.87M |
$3.39
+0.89%
|
|
TNX-1700 (TFF2 fusion protein) is an oncology program, placing it in biotech oncology.
|
$155.21M |
$21.19
-4.46%
|
|
Actuate Therapeutics is a biotech company focused on oncology, developing cancer therapies (elraglusib) with clinical-stage programs.
|
$152.84M |
$7.79
-4.06%
|
|
Direct oncology biotech focus; Cardiff Oncology's lead asset is an oncology drug (onvansertib).
|
$147.02M |
$2.21
-7.14%
|
|
Company's pipeline is focused on oncology, aligning with NXP900/NXP800 programs.
|
$140.86M |
$5.96
-0.33%
|
|
Atossa's lead candidate targets metastatic breast cancer, a core oncology focus in biotech/pharma.
|
$139.50M |
$1.08
-7.69%
|
|
Anixa's core focus is oncology-biotech with direct development of cancer therapies, fitting Biotech - Oncology.
|
$139.47M |
$4.33
-12.35%
|
|
Pipeline includes oncology indications (e.g., TVGN 920 for cervical cancer, TVGN 930 for EBV-associated lymphomas), placing the company in Biotech - Oncology.
|
$131.50M |
$0.72
-3.36%
|
|
Company operates as an oncology-focused biotechnology developer.
|
$126.15M |
$19.23
-8.43%
|
|
Company focuses on oncology DARPin therapeutics as a core business line, including lead AML/MDS program (MP0533) and RDTs.
|
$126.14M |
$3.80
+1.06%
|
|
TScan Therapeutics develops cancer immunotherapies in oncology, focusing on targeted TCR-T approaches.
|
$125.07M |
$2.21
+0.45%
|
|
Lead asset azenosertib is an oncology-focused small molecule targeting WEE1, aligning with Biotech - Oncology.
|
$115.84M |
$1.59
-0.93%
|
|
Oncology diagnostics pipeline (DetermaIO, DetermaCNI) represents core oncology biotech offerings.
|
$111.25M |
$3.89
+2.37%
|
|
Historical oncology programs (e.g., SL-172154, SL-279252) signal prior Biotech Oncology activity.
|
$109.21M |
$2.28
+1.33%
|
|
Agenus' core oncology program centers on botensilimab (BOT) and balstilimab (BAL), a differentiated immuno-oncology therapy portfolio.
|
$108.84M |
$3.97
-6.81%
|
|
Ex vivo gene-edited cell therapies for cancer place MGX in the oncology biotech space.
|
$106.91M |
$2.86
-8.04%
|
|
Core focus on antibody-based oncology therapeutics (bispecifics and ADCs) directly aligns with Biotech - Oncology.
|
$106.62M |
$1.69
-4.52%
|
|
EUDA is pursuing T-cell immunotherapy initiatives with oncology applications, aligning with cancer immunotherapy programs.
|
$102.23M |
$2.86
+4.38%
|
|
ALXO is a biotech oncology company advancing immuno-oncology therapies (CD47 and ADCs).
|
$99.94M |
$1.76
-5.88%
|
|
INO-3112 and other oncology efforts place INOVIO in the cancer therapeutics space, supported by DNA medicine–based approaches.
|
$94.25M |
$2.57
-1.91%
|
|
Ebvallo targets EBV-driven cancers (EBV+ PTLD), placing Atara in oncology.
|
$93.18M |
$15.09
-3.45%
|
|
Pelareorep is a cancer-focused oncolytic virus immunotherapy, which directly constitutes the company's core oncology product.
|
$92.49M |
$1.20
-5.51%
|
|
PLRX's PLN-101095 is an oncology program targeting ICI-refractory solid tumors, making Biotech - Oncology a core segment.
|
$91.47M |
$1.49
-2.61%
|
|
Direct focus on oncology; Champions Oncology specializes in oncology translational research and PDX-based models.
|
$90.10M |
$6.54
-0.46%
|
|
Directly operates as an oncology-focused biotechnology company developing antibody-based cancer immunotherapies.
|
$86.33M |
$1.95
-1.52%
|
|
Burning Rock Biotech operates in oncology biotechnology with MRD and MCED testing, a core oncology diagnostics business.
|
$86.30M |
$8.36
-4.46%
|
|
Company focuses on oncology immunotherapies, a primary Biotech oncology segment.
|
$81.01M |
$0.89
-1.06%
|
|
Fortress's portfolio includes oncology-focused assets (e.g., Mustang Bio's cell therapies and CHKP's oncology programs).
|
$80.13M |
$2.71
-3.56%
|
|
Covers Adicet's focus on oncology applications (solid tumors) through ADI-212 and cancer-directed cell therapies.
|
$80.00M |
$0.97
+5.13%
|
|
ROLVEDON is Assertio's growth asset in oncology support care (a long-acting G-CSF), linking to oncology/biotech therapeutics.
|
$79.98M |
$0.83
-4.47%
|
|
HPV therapeutic vaccine program aligns with oncology-focused Biotech therapies.
|
$79.22M |
$0.35
-1.41%
|
|
Company develops True Human monoclonal antibodies for oncology and related immune/inflammatory indications (IL-1a pathway), a core biotech product line.
|
$77.44M |
$2.54
-3.05%
|
|
Direct focus on oncology therapies (lead candidates RP-3467 and RP-1664) and the SNIPRx platform positions Repare as a biotech oncology company.
|
$77.20M |
$1.80
-1.10%
|
|
IGM Biosciences is developing oncology-targeted antibody therapies, with an active clinical pipeline in cancer indications.
|
$76.35M |
$1.27
|
|
Company focuses on oncology immunotherapies (IL-2/IL-12 INDUKINEs, IL-10 INDUKINE, STEAP1-targeted engager) under the PREDATOR platform.
|
$73.14M |
$1.63
-9.94%
|
|
Company pursues cancer treatment platforms and immunomodulatory approaches, aligning with oncology biotechnology.
|
$71.79M |
$2.10
|
|
Core oncology-focused biotechnology developing targeted therapies (SMARCA2 degraders, KAT6A degraders, and antibody-drug conjugates).
|
$71.14M |
$1.26
-9.35%
|
|
Company is a biotechnology focused on oncology, explicitly described as developing cancer therapies.
|
$70.66M |
$1.38
|
|
Lead oncology asset Plinabulin positions BeyondSpring in cancer therapeutics, aligning with Biotech - Oncology.
|
$70.15M |
$1.74
-4.92%
|
|
Biotech - Oncology focus; Sutro specializes in cancer therapeutics, particularly ADC-based approaches for solid tumors.
|
$67.88M |
$0.80
-5.80%
|
|
NDV-01 and Sepranolone are drug candidates developed by Relmada in oncology and neuropsychiatry, aligning with Biotech - Oncology.
|
$67.71M |
$2.04
-8.93%
|
|
Glioblastoma is listed as a potential indication, aligning with the oncology biotech space ('Biotech - Oncology').
|
$62.78M |
$1.28
+3.23%
|
|
Cue Biopharma is developing oncology immunotherapies (CUE-101, CUE-102) using its Immuno-STAT platform.
|
$59.94M |
$0.80
-14.46%
|
|
Core oncology-focused biotech company delivering cancer therapies (ACR-368, ACR-2316) and diagnostics.
|
$59.89M |
$1.91
+1.60%
|
Showing page 2 of 4 (324 total stocks)
Loading industry metrics...
Loading comparison data...
